請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20281
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 趙福杉 | |
dc.contributor.author | Yu-Sen Huang | en |
dc.contributor.author | 黃昱森 | zh_TW |
dc.date.accessioned | 2021-06-08T02:44:01Z | - |
dc.date.copyright | 2018-02-26 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2018-01-22 | |
dc.identifier.citation | Baker, S., Dahele, M., Lagerwaard, F.J. and Senan, S. (2016). 'A critical review of recent developments in radiotherapy for non-small cell lung cancer.' Radiat Oncol 11(1): 115.
Chang, R.F., Chen, H.H., Chang, Y.C., Huang, C.S., Chen, J.H. and Lo, C.M. (2016). 'Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.' Magn Reson Imaging 34(6): 809-819. Chang, Y.C., Yu, C.J., Chen, C.M., Hu, F.C., Hsu, H.H., Tseng, W.Y., Ting-Fang Shih, T., Yang, P.C. and Chih-Hsin Yang, J. (2012). 'Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.' J Magn Reson Imaging 36(2): 387-396. Chen, B.B., Hsu, C.Y., Yu, C.W., Liang, P.C., Hsu, C., Hsu, C.H., Cheng, A.L. and Shih, T.T. (2016). 'Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma.' Eur Radiol. Chen, F.H., Chiang, C.S., Wang, C.C., Tsai, C.S., Jung, S.M., Lee, C.C., McBride, W.H. and Hong, J.H. (2009). 'Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors.' Clin Cancer Res 15(5): 1721-1729. Cheng, J.C., Yuan, A., Chen, J.H., Lu, Y.C., Cho, K.H., Wu, J.K., Wu, C.J., Chang, Y.C. and Yang, P.C. (2013). 'Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic contrast-enhanced MRI.' PLoS One 8(5): e62762. Cox, J.D., Stetz, J. and Pajak, T.F. (1995). 'Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).' Int J Radiat Oncol Biol Phys 31(5): 1341-1346. d'Arcy, J.A., Collins, D.J., Padhani, A.R., Walker-Samuel, S., Suckling, J. and Leach, M.O. (2006). 'Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data.' Radiographics 26(2): 621-632. Davnall, F., Yip, C.S., Ljungqvist, G., Selmi, M., Ng, F., Sanghera, B., Ganeshan, B., Miles, K.A., Cook, G.J. and Goh, V. (2012). 'Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?' Insights Imaging 3(6): 573-589. de Langen, A.J., van den Boogaart, V., Lubberink, M., Backes, W.H., Marcus, J.T., van Tinteren, H., Pruim, J., Brans, B., Leffers, P., Dingemans, A.M., Smit, E.F., Groen, H.J. and Hoekstra, O.S. (2011). 'Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.' J Nucl Med 52(1): 48-55. Donaldson, S.B., Buckley, D.L., O'Connor, J.P., Davidson, S.E., Carrington, B.M., Jones, A.P. and West, C.M. (2010). 'Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix.' Br J Cancer 102(1): 23-26. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2015). 'Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.' Int J Cancer 136(5): E359-386. Galban, S., Brisset, J.C., Rehemtulla, A., Chenevert, T.L., Ross, B.D. and Galban, C.J. (2010). 'Diffusion-weighted MRI for assessment of early cancer treatment response.' Curr Pharm Biotechnol 11(6): 701-708. Grutters, J.P., Kessels, A.G., Pijls-Johannesma, M., De Ruysscher, D., Joore, M.A. and Lambin, P. (2010). 'Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis.' Radiother Oncol 95(1): 32-40. Heijmen, L., Verstappen, M.C., Ter Voert, E.E., Punt, C.J., Oyen, W.J., de Geus-Oei, L.F., Hermans, J.J., Heerschap, A. and van Laarhoven, H.W. (2012). 'Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?' Crit Rev Oncol Hematol 83(2): 194-207. Heusch, P., Buchbender, C., Kohler, J., Nensa, F., Gauler, T., Gomez, B., Reis, H., Stamatis, G., Kuhl, H., Hartung, V. and Heusner, T.A. (2014). 'Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.' J Nucl Med 55(3): 373-378. Heusch, P., Kohler, J., Wittsack, H.J., Heusner, T.A., Buchbender, C., Poeppel, T.D., Nensa, F., Wetter, A., Gauler, T., Hartung, V. and Lanzman, R.S. (2013). 'Hybrid [(1)(8)F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).' Eur J Radiol 82(11): 2055-2060. Heusch, P., Nensa, F., Schaarschmidt, B., Sivanesapillai, R., Beiderwellen, K., Gomez, B., Kohler, J., Reis, H., Ruhlmann, V. and Buchbender, C. (2015). 'Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.' Eur J Nucl Med Mol Imaging 42(1): 42-48. Huang, Y.S., Chen, J.L., Hsu, F.M., Huang, J.Y., Ko, W.C., Chen, Y.C., Jaw, F.S., Yen, R.F. and Chang, Y.C. (2017). 'Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.' J Magn Reson Imaging. Iizuka, Y., Matsuo, Y., Umeoka, S., Nakamoto, Y., Ueki, N., Mizowaki, T., Togashi, K. and Hiraoka, M. (2014). 'Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.' Eur J Radiol 83(11): 2087-2092. Jackson, A., O'Connor, J.P., Parker, G.J. and Jayson, G.C. (2007). 'Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.' Clin Cancer Res 13(12): 3449-3459. Jeong, J.U., Chung, W.K., Nam, T.K., Song, J.Y., Yoon, M.S., Kim, Y.C., Kim, K.S., Oh, I.J., Ban, H.J., Kwon, S.Y., Bom, H.S. and Ahn, S.J. (2014). 'Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.' Anticancer Res 34(5): 2517-2523. Lagerwaard, F.J., Verstegen, N.E., Haasbeek, C.J., Slotman, B.J., Paul, M.A., Smit, E.F. and Senan, S. (2012). 'Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.' Int J Radiat Oncol Biol Phys 83(1): 348-353. Leach, M.O., Brindle, K.M., Evelhoch, J.L., Griffiths, J.R., Horsman, M.R., Jackson, A., Jayson, G.C., Judson, I.R., Knopp, M.V., Maxwell, R.J., McIntyre, D., Padhani, A.R., Price, P., Rathbone, R., Rustin, G.J., Tofts, P.S., Tozer, G.M., Vennart, W., Waterton, J.C., Williams, S.R. and Workman, P. (2005). 'The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.' Br J Cancer 92(9): 1599-1610. Nair, V.J., MacRae, R., Sirisegaram, A. and Pantarotto, J.R. (2014). 'Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.' Int J Radiat Oncol Biol Phys 88(2): 312-318. O'Rourke, N., Roque, I.F.M., Farre Bernado, N. and Macbeth, F. (2010). 'Concurrent chemoradiotherapy in non-small cell lung cancer.' Cochrane Database Syst Rev(6): Cd002140. Ohno, Y., Koyama, H., Yoshikawa, T., Matsumoto, K., Aoyama, N., Onishi, Y. and Sugimura, K. (2012). 'Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.' AJR Am J Roentgenol 198(1): 75-82. Onishi, H., Shirato, H., Nagata, Y., Hiraoka, M., Fujino, M., Gomi, K., Niibe, Y., Karasawa, K., Hayakawa, K., Takai, Y., Kimura, T., Takeda, A., Ouchi, A., Hareyama, M., Kokubo, M., Hara, R., Itami, J., Yamada, K. and Araki, T. (2007). 'Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.' J Thorac Oncol 2(7 Suppl 3): S94-100. Padhani, A.R. and Husband, J.E. (2000). 'Commentary. Are current tumour response criteria relevant for the 21st century?' Br J Radiol 73(874): 1031-1033. Padhani, A.R. and Koh, D.M. (2011). 'Diffusion MR imaging for monitoring of treatment response.' Magn Reson Imaging Clin N Am 19(1): 181-209. Postmus, P.E., Kerr, K.M., Oudkerk, M., Senan, S., Waller, D.A., Vansteenkiste, J., Escriu, C. and Peters, S. (2017). 'Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.' Ann Oncol 28(suppl_4): iv1-iv21. Ramnath, N., Dilling, T.J., Harris, L.J., Kim, A.W., Michaud, G.C., Balekian, A.A., Diekemper, R., Detterbeck, F.C. and Arenberg, D.A. (2013). 'Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.' Chest 143(5 Suppl): e314S-e340S. Schaarschmidt, B.M., Grueneisen, J., Metzenmacher, M., Gomez, B., Gauler, T., Roesel, C., Heusch, P., Ruhlmann, V., Umutlu, L., Antoch, G. and Buchbender, C. (2017). 'Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?' Eur Radiol 27(2): 681-688. Sobin, L.H., Gospodarowicz, M.K. and Wittekind, C. (2009). TNM Classification of Malignant Tumours, 7th Edition. New Jersey, Wiley-Blackwell. Song, C.W., Kim, M.S., Cho, L.C., Dusenbery, K. and Sperduto, P.W. (2014). 'Radiobiological basis of SBRT and SRS.' Int J Clin Oncol 19(4): 570-578. Sung, Y.S., Park, B., Choi, Y., Lim, H.S., Woo, D.C., Kim, K.W. and Kim, J.K. (2016). 'Dynamic contrast-enhanced MRI for oncology drug development.' J Magn Reson Imaging 44(2): 251-264. Tao, X., Wang, L., Hui, Z., Liu, L., Ye, F., Song, Y., Tang, Y., Men, Y., Lambrou, T., Su, Z., Xu, X., Ouyang, H. and Wu, N. (2016). 'DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC.' Sci Rep 6: 35569. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. and Gwyther, S.G. (2000). 'New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.' J Natl Cancer Inst 92(3): 205-216. Timmerman, R., Paulus, R., Galvin, J., Michalski, J., Straube, W., Bradley, J., Fakiris, A., Bezjak, A., Videtic, G., Johnstone, D., Fowler, J., Gore, E. and Choy, H. (2010). 'Stereotactic body radiation therapy for inoperable early stage lung cancer.' Jama 303(11): 1070-1076. Tofts, P.S., Brix, G., Buckley, D.L., Evelhoch, J.L., Henderson, E., Knopp, M.V., Larsson, H.B., Lee, T.Y., Mayr, N.A., Parker, G.J., Port, R.E., Taylor, J. and Weisskoff, R.M. (1999). 'Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.' J Magn Reson Imaging 10(3): 223-232. Vansteenkiste, J., De Ruysscher, D., Eberhardt, W.E., Lim, E., Senan, S., Felip, E. and Peters, S. (2013). 'Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.' Ann Oncol 24 Suppl 6: vi89-98. Warner, A., Dahele, M., Hu, B., Palma, D.A., Senan, S., Oberije, C., Tsujino, K., Moreno-Jimenez, M., Kim, T.H., Marks, L.B., Rengan, R., De Petris, L., Ramella, S., De Ruyck, K., De Dios, N.R., Bradley, J.D. and Rodrigues, G. (2016). 'Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.' Int J Radiat Oncol Biol Phys 94(3): 612-620. Yoon, S.H., Goo, J.M., Lee, S.M., Park, C.M., Seo, H.J. and Cheon, G.J. (2014). 'Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: current status and future prospects.' J Thorac Imaging 29(1): 4-16. Yoon, S.H., Park, C.M., Park, S.J., Yoon, J.H., Hahn, S. and Goo, J.M. (2016). 'Tumor Heterogeneity in Lung Cancer: Assessment with Dynamic Contrast-enhanced MR Imaging.' Radiology 280(3): 940-948. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20281 | - |
dc.description.abstract | 肺癌近幾年居國人十大癌症死因排行榜的第一位。非小細胞肺癌約佔所有肺癌病人數之85%以上。身體立體定位放射治療為無法開刀的早期肺癌病人之首選治療,而治癒性化學放射治療則為局部晚期肺癌病人之標準治療。目前尚無準確的影像學方法可於治療初期優先預測腫瘤治療後之反應。整合型磁振正子掃描是一種新型影像技術,可早期評估腫瘤對於放射治療的反應,希望能儘早預測疾病進展和病人存活。
在本研究的第一部分,我們前瞻性納入了17例接受身體立體定位放射治療的非轉移性非小細胞肺癌早期患者。我們分析正子掃描之標準攝取值,核磁共振之動態顯影掃描影像參數,及擴散加權影像參數,包括:腫瘤大小、SUV、ADC、Ktrans、kep、ve、vp及iAUC60。結果顯示,整合型磁振正子掃描可測量身體立體定位放射治療後之腫瘤參數變化,如SUVmax(p <0.001)、Ktrans平均值(p = 0.005)、Ktrans標準差(p = 0.046)、kep平均值(p = 0.014)、kep 標準差(p = 0.001)和vp 標準差(p = 0.002)。正子掃描相關參數SUVmax與磁振掃描相關參數kep平均值(p = 0.002)和kep 標準差(p < 0.001)呈顯著線性相關。在身體立體定位放射治療後6週,Ktrans平均值下降之百分比(p < 0.001)及kep平均值下降之百分比(p = 0.034),此兩者皆與腫瘤大小縮小之百分比呈顯著線性相關。 在本研究的第二部分,我們前瞻性納入17例接受治癒性化學放射治療的非轉移性非小細胞肺癌局部晚期患者。結果顯示,整合型磁振正子掃描可測量化學放射治療後之腫瘤參數變化,如SUVmax(p <0.001)、Ktrans平均值(p = 0.004)、Ktrans標準差(p = 0.022)、kep平均值(p = 0.016)、kep 標準差(p = 0.018)、vp標準差(p < 0.001)和iAUC60(p = 0.014)。化學放射治療後SUVmax仍大於10的病人,肺癌局部復發之風險較高(p <0.001),且總體生存期較短(p = 0.006)。在回歸分析中,化學放射治療後SUVmax小於5、Ktrans降低且ADC增加的病人,對治療效果較好,腫瘤局部復發或遠端轉移之風險較低 (Hazard ratio: 1.0),化學放射治療後SUVmax仍大於5且Ktrans增加的病人,對治療效果差,腫瘤局部復發或遠端轉移之風險高 (Hazard ratio: 11.5)。 根據上述結果,我們證明了此新型影像技術精準結合了正子掃描及核磁共振之優點,在同一次檢查中即可對腫瘤進行深入評估;整合型磁振正子掃描確實可以早期評估腫瘤對於放射治療的反應,並可有效預測局部治療反應、疾病進展及病人存活。 | zh_TW |
dc.description.abstract | Dynamic contrast-enhanced (DCE) integrated magnetic resonance positron emission tomography (MR-PET) is a novel image technique for earlier evaluation of tumor response to radiotherapy, leading to earlier predicting disease progression and patients’ survival. Stereotactic body radiotherapy (SBRT) is a standard treatment option for patients with stage I non-small cell lung cancer (NSCLC), and chemoradiotherapy (CRT) is the treatment of choice for patients with unresectable or locally advanced stage III NSCLC.
In the first part of the study, we prospectively enrolled 19 lung tumors in 17 non-metastatic NSCLC patients who were receiving SBRT as a primary treatment. They underwent DCE-integrated MR-PET before and 6 weeks after SBRT. The following image parameters were analysed: tumor size, standardized uptake value (SUV), apparent diffusion coefficient, Ktrans, kep, ve, vp, and iAUC60. Chest computed tomography (CT) was performed at 3 months after SBRT. The results showed that SBRT treatment led to a functional change in the tumor, as demonstrated by significant decreases in the SUVmax (p<0.001), Ktrans mean (p=0.005), Ktrans standard deviation (SD; p=0.046), kep mean (p= 0.014), kep SD values (p=0.001), and vp SD (p=0.002). The PET functional value SUVmax was correlated with the MR functional values kep mean (p=0.002) and kep SD (p<0.001). The percentage reduction in Ktrans mean (p<0.001) and kep mean ( p=0.034) at 6 weeks post-SBRT were significantly correlated with the percentage reduction in tumor size, as measured using CT at 3 months after SBRT. Univariate analyses revealed a trend toward disease progression when the initial SUVmax > 10 (p=0.083). In the second part of the study, we prospectively enrolled 17 non-metastatic NSCLC patients receiving CRT as primary treatment. The results showed that CRT led to tumor significant decreases in SUVmax (p < 0.001), Ktrans mean and standard deviation (SD, p = 0.004 and 0.022, respectively), kep mean and SD (p = 0.016 and 0.018, respectively), vp SD (p < 0.001), and iAUC60 (p = 0.014). The median follow-up time was 12.0 months. Patients with post-CRT SUVmax > 10 were prone to local failures and poor overall survival (p < 0.001 and p = 0.006, respectively). In proportional hazards regression analyses via the stratified Cox model, we identified post-CRT SUVmax >5 and increasing Ktrans as predictor of local failure and distant metastasis (Hazard ratio: 11.5), as well as poor patient survival. In conclusions, DCE-integrated MR-PET imaging seems to be a promising addition to clinical examination and anatomic imaging for assessing the response of NSCLC to radiation therapy. This technology which combines PET and MRI facilitates the in-depth assessment of tumors in a single examination. In patients with NSCLC who are receiving radiation therapy, DCE-integrated MR-PET with parameters allows clinicians to evaluate the response early after radiation therapy, and to predict the local treatment response, disease progression, and survival. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:44:01Z (GMT). No. of bitstreams: 1 ntu-106-D03548002-1.pdf: 2566325 bytes, checksum: 8941b478f50c789694c2ebd460d9c44a (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………... i
誌謝……………………………………………………………………………… ii 中文摘要………………………………………...………………………………. iii 英文摘要………………………………………...……………………….……… v 縮寫對照表……………………………………………………………….……... vii Chapter One: Introduction 1 1.1 Non–Small Cell Lung Cancer 1 1.2 Stereotactic body radiotherapy 1 1.3 Chemoradiotherapy 2 1.4 Dynamic Contrast-Enhanced Integrated MR-PET 2 1.5 Apparent diffusion coefficient (ADC) value on diffusion-weighted MRI….3 Chapter Two: Evaluating SBRT Treatment Response by MR-PET 4 2.1 Purpose 4 2.2 Materials and Methods 4 2.3 Results 10 Chapter Three: Evaluating CRT Treatment Response by MR-PET 21 3.1 Purpose 21 3.2 Materials and Methods 21 3.3 Results 26 Chapter Four: Discussion 37 4.1 Evaluating SBRT Treatment Response by MR-PET 37 4.2 Evaluating CRT Treatment Response by MR-PET 41 Chapter Five: Conclusions 43 References 45 Appendix 49 | |
dc.language.iso | en | |
dc.title | 磁振正子掃描於非小細胞肺癌放射線治療療效評估之應用 | zh_TW |
dc.title | Application of MR-PET in radiotherapy treatment response evaluation of non-small cell lung cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張允中,陳中明,陳右穎,黃基礎 | |
dc.subject.keyword | 磁振正子掃描,動態顯影,非小細胞肺癌,放射線治療,療效評估, | zh_TW |
dc.subject.keyword | MR-PET,Dynamic contrast-enhanced,Non-small cell lung cancer,Radiotherapy,Treatment response evaluation, | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU201800096 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-01-22 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.51 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。